Compare Nuvalent Inc (NUVL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Regeneron Pharmaceuticals Inc trades at $673.67 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 7.2× Nuvalent Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| NUVL | REGN | |
|---|---|---|
Market Cap | $9.81B | $70.47B |
Sector | Technology | Health |
52-Week High | $123.96 | $812.27 |
52-Week Low | $72.16 | $545.46 |
Enterprise Value | $8.52B | $64.42B |
Dividend Yield | — | 0.56% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
